India, April 24 -- Lucid Diagnostics Inc. (LUCD), a subsidiary of PAVmed Inc. (PAVM), Thursday reported positive data from a National Cancer Institute (NCI)-sponsored study of its EsoGuard Esophageal DNA Test in patients without symptoms of chronic gastroesophageal reflux disease (GERD).
The study was conducted at Case Western Reserve University (CWRU) and University Hospitals (UH) and enrolled patients without GERD symptoms who otherwise met American Gastroenterological Association (AGA) recommendations for esophageal precancer (Barrett's Esophagus or BE) screening.
In the study, EsoGuard showed excellent negative predictive value (NPV) of 100% for detecting esophageal precancer, consistent with its unprecedented precancer detection repo...